Back to search
FDAFDA · Food and drugs·Recall number Z-0507-2013

Siemens Healthcare BR Assay for CA 27.29 250 Test Kits 03896216 50 Test Kit 02419937 Ref Kit (US only) 10340081 Intended Use The ADVIA Centaur BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur and ADVIA Centaur XP systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage Ill breast cancer.

Published December 19, 2012 · Recall initiated: November 14, 2012

Summary

FDA records medical device Class II recall Z-0507-2013, published December 19, 2012 and initiated November 14, 2012. Recalling firm: Siemens Healthcare Diagnostics, Inc; Status: Terminated; Reported quantity: 250 test =1678 and 50 test =2660 and Ref. 1196; Lot: All lot codes. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc
Distributor
Worldwide Distribution - USA (nationwide) and Internationally to the following countries: Argentina Australia Austria Azerbaijan Belgium Bosnia Herzeg. Brazil Canada Chile COLOMBIA Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hong Kong Hungary Iceland India Indonesia Iran Ireland Italy Japan Kazakhstan Latvia Lithuania Malaysia Mexico Netherlands New Caledonia Norway Oman P.R. China Philippines Poland Portugal Qatar Rep. of Yemen Republic Korea Reunion Romania Russian Fed. Saudi Arabia Serbia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Thailand Turkey U.A.E. United Kingdom Uruguay Vietnam
Lot
All lot codes
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Siemens Healthcare BR Assay for CA 27.29 250 Test Kits 03896216 50 Test Kit 02419937 Ref Kit (US only) 10340081 Intended Use The ADVIA Centaur BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur and ADVIA Centaur XP systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage Ill breast cancer. recalled?

Yes. FDA published recall Z-0507-2013 on December 19, 2012. Reported hazard: Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.

What should I do if I have this product?

Voluntary: Firm initiated · Letter